BioCentury | Jul 19, 2018
Translation in Brief

Public Funding Highlights: 2Q18

Public Funding Highlights: 2Q18 Selected developments and initiatives in 2Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI) and the...
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...assay for real-time monitoring of cell metabolism. Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO...
...CEO. He was CFO at Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) and has been on Taro's...
...International Inc. Kane Biotech Inc. Merus Labs International Inc. Norgine B.V. Rugen Therapeutics Co. Ltd. Sanofi Sun Pharmaceutical Industries Ltd. SymCel Sverige AB Taro...
BioCentury | Feb 17, 2017
Finance

Tokyo connection

...biotechs, including those with academic origins in Japan (see BioCentury, Aug. 4, 2014) . Remiges' Taro...
...pharma." "We differentiate ourselves by having a strong connection with Japanese academia and Japanese pharma." Taro...
BioCentury | Feb 14, 2017
Financial News

Remiges tops off $80M biotech fund

...1Globe Capital. Remiges invests in early stage biotechs in the U.S. and Europe. Managing partner Taro...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Infectious disease

...infection (SSSI); Staphylococcus Cell culture and mouse studies suggest inhibiting the Staphylococcus aureus biosynthetic proteins tarO...
...tarO and tarH in abscess models. TARGET/MARKER/PATHWAY: S. aureus wall teichoic acid biosynthesis protein tarO (tarO...
...aureus wall teichoic acid biosynthesis protein tarH (tarH) S. aureus wall teichoic acid biosynthesis protein tarO (tarO) Staphylococcus...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...protein kininogen, which is in Phase II for acute external otitis. And NovaBiotics Ltd. and Taro...
...Aberdeen, U.K. Pergamum AB, Solna, Sweden Riptide Bioscience Inc., Vallejo, Calif. Taro Pharmaceutical Industries Ltd. (NYSE:TARO...
BioCentury | Dec 3, 2016
Company News

Management tracks

...Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO) said Uday Baldota will replace Kal Sundaram...
...Ltd. (BSE:524715; NSE:SUNPHARMA). Abhay Gandhi, who is CEO of Sun's North America operations, will be Taro's...
BioCentury | Oct 31, 2016
Company News

Vanda, Taro Pharmaceutical deal

...Vanda granted Taro non-exclusive, U.S. rights to manufacture and commercialize a generic version of Vanda’s Fanapt...
...schizophrenia in adults. Taro did not respond to inquiries. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Taro...
...did not respond to inquiries. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Taro Pharmaceutical Industries Ltd. (NYSE:TARO...
BioCentury | Jul 1, 2016
Company News

Management tracks

...SVP and CFO. Kalb was CFO and chief accounting officer at Taro Pharmaceutical Industries Ltd. (NYSE:TARO...
BioCentury | Jun 13, 2016
Finance

Small price of progress

...the single-digit millions instead of eliminating all the funding risk from the outset," added Remiges' Taro...
Items per page:
1 - 10 of 36